Bob Hoffman co-founded Khartis in 2023 and serves as the Chief Executive Officer and Head of Research. Prior to Khartis, Bob was the Vice President of Chemistry at XinThera, leading the discovery of PARP1 selective (peripheral and CNS available) and MK2 Development Candidates purchased by Gilead Sciences in May 2023.   

Prior to XinThera, Bob had a successful 32-year career at Pfizer which included being a key contributor to the discovery of Lorbrena®, project co-lead or inventor of the CDK2/4/6 inhibitor ebvaciclib, the CDK2 selective inhibitor PF-07104091, the SARS-CoV-2 Mpro inhibitor lufotrelvir, and five additional clinical candidates. Bob is an author of over 60 patents and papers, the 1999 recipient of the ACS Technical Achievements in Organic Chemistry award and the 2021 ACS Heroes of Chemistry award.